ASML Reports Strong Q3 and Raised Capacity Plans, Yet Shares Fall Amid Execution and Valuation Concerns

What happened

ASML reported robust Q3 2026 results and guided to accelerating Q4 revenue growth, while management also announced an increase in capacity expansion plans for 2028. Despite these positive operational signals, ASML shares fell in October, reflecting investor concerns about the company's elevated valuation, execution risk in scaling capacity, and lingering China export-control uncertainty that have already been identified in our prior research. The new information on 2028 capacity expansion aligns with management's previously stated intent but adds little incremental clarity on whether ASML can convert record demand into on-time shipments without margin erosion. The stock's decline in response to strong near-term numbers suggests the market is now more focused on supply-side bottlenecks and policy risk than on demand confirmation, which supports our existing WAIT rating. We continue to view ASML as a high-quality franchise with strong long-term demand, but at current levels the risk/reward remains unattractive, and we would wait for either a lower entry price or clearer evidence that capacity expansion will translate into sustained earnings growth.

Implication

The October share decline despite strong fundamentals reinforces that ASML's current valuation already embeds flawless execution, and any hint of supply-chain or policy friction can trigger sharp de-rating. Our base case still implies a fair value of around $1,800, but the wide range of outcomes—from $1,450 in a bear scenario to $2,000 in a bull scenario—makes the stock unsuitable for new capital at the current price of roughly $1,748. Investors should monitor near-term catalysts including ASML's next quarterly guidance, any updates on 2027 and 2028 capacity expansion, and customer capex trends from TSMC, Micron, and Samsung, as these will determine whether the stock can break out or continues to consolidate. China remains a key swing factor; if export controls tighten further or China sales fall below 15% of total before non-China demand can offset, our bear case becomes more likely and a pullback toward $1,450 could occur. For existing holders, we suggest holding positions but trimming above $1,900, while waiting for either a more compelling entry price or concrete evidence of capacity conversion to add exposure.

Thesis delta

The new report of strong Q3 results and Q4 acceleration mildly reinforces our demand thesis, but the confirmation of increased 2028 capacity plans does not alter our WAIT rating. The market's negative reaction in October suggests that execution risk and valuation are now the dominant concerns, and thus our base case remains unchanged with an implied value of $1,800 and attractive entry at $1,550.